LGD-4033 and Trenbolone Interaction

Avoid
Mechanism-based 64% confidence

LGD-4033 and Trenbolone have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Trenbolone

19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent

Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle.

Half-life: ~3 days (acetate) Typical dose: 200-400 mg/week anabolic
androgen receptoraromataseigf1ngf androgenicblood pressure raisingcarcinogenic riskcardiotoxic
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 androgenic compounds (LGD-4033, Trenbolone). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (LGD-4033, Trenbolone). Monitor BP daily and consider cardiovascular support.
2x 2 compounds share the carcinogenic-risk safety flag (LGD-4033, Trenbolone). Monitor accordingly.
2x 2 estrogenic compounds (LGD-4033, Trenbolone). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 hepatotoxic compounds (LGD-4033, Trenbolone). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (LGD-4033, Trenbolone). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (LGD-4033, Trenbolone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Trenbolone). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Trenbolone?

Combining LGD-4033 with Trenbolone is not recommended. Both LGD-4033 and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Trenbolone safe together?

This combination carries significant risk. Both LGD-4033 and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Trenbolone?

Both LGD-4033 and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Trenbolone?

LGD-4033 has a half-life of ~24-36 hours and Trenbolone has a half-life of ~3 days (acetate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Trenbolone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.